Takeda Collaborates with Charles River to Identify and Develop Preclinical Candidates

 Takeda Collaborates with Charles River to Identify and Develop Preclinical Candidates

Takeda Collaborates with Charles River to Identify and Develop Preclinical Candidates

Shots:

  • Charles River to receive up front, up to $50M as development milestones/ program, up to $120M as commercial milestones and royalties on net sales of the developed products.
  • Takeda to launch multiple integrated programs targeting its four core therapeutic areas (oncology, gastroenterology, neuroscience, and rare disease) and will get an option to advance the preclinical candidates via their clinical development pipeline
  •  The agreement combines Charles’ drug discovery expertise and deep scientific bench with Takeda’s investments in human data and translation to deliver transformative therapies to the needy patients

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post